Citations

Clear

13603 citation(s) found for "_, _".

Past, Present, and Future of Viral Vector Vaccine Platforms: A Comprehensive Review
Tang, Justin , Campian, Jian , Amin, Md Al, Amin, Md. Al

Mayo Clinic

Vaccines | May 15, 2025 | Volume: 13 | Issue: 5 | Pages: 524

10.3390/vaccines13050524 | PMID 40432133 Get It

Over the past several decades, viral vector-based vaccines have emerged as some of the most versatile and potent platforms in modern vaccinology. Their capacity to deliver genetic material encoding target antigens directly into host cells enables strong cellular and humoral immune responses, often superior to what traditional inactivated or subunit vaccines can achieve. This has accelerated their application to a wide array of pathogens and disease targets, from well-established threats like HIV and malaria to emerging infections such as Ebola, Zika, and SARS-CoV-2. The COVID-19 pandemic further highlighted the agility of viral vector platforms, with several adenovirus-based vaccines quickly authorized and deployed on a global scale. Despite these advances, significant challenges remain. One major hurdle is pre-existing immunity against commonly used vector backbones, which can blunt vaccine immunogenicity. Rare but serious adverse events, including vector-associated inflammatory responses and conditions like vaccine-induced immune thrombotic thrombocytopenia (VITT), have raised important safety considerations. Additionally, scaling up manufacturing, ensuring consistency in large-scale production, meeting rigorous regulatory standards, and maintaining equitable global access to these vaccines present profound logistical and ethical dilemmas. In response to these challenges, the field is evolving rapidly. Sophisticated engineering strategies, such as integrase-defective lentiviral vectors, insect-specific flaviviruses, chimeric capsids to evade neutralizing antibodies, and plug-and-play self-amplifying RNA approaches, seek to bolster safety, enhance immunogenicity, circumvent pre-existing immunity, and streamline production. Lessons learned from the COVID-19 pandemic and prior outbreaks are guiding the development of platform-based approaches designed for rapid deployment during future public health emergencies. This review provides an exhaustive, in-depth examination of the historical evolution, immunobiological principles, current platforms, manufacturing complexities, regulatory frameworks, known safety issues, and future directions for viral vector-based vaccines.
Outcomes and Characteristics of Mesenchymal Tumors Involving the Parotid Gland
Baratz, Hannah , Moore, Eric J. , Molligan, Jeremy , Tasche, Kendall K. , Abel, Kathryn M. Van , Baratz, Hannah Q , Yin, Linda X , Van Abel, Kathryn M , Yin, Linda X. , Price, Daniel L.

Mayo Clinic

Annals of Otology, Rhinology & Laryngology | May 15, 2025 | Volume: 134 | Issue: 8 | Pages: 583-587

10.1177/00034894251336840 | PMID 40370050 Get It

Background: Malignant mesenchymal tumors involving the parotid gland are uncommon, characteristically aggressive, and little is known with few reports documented. Study Design: Retrospective case series. Setting: Single institution tertiary care center, 2010 to 2022. Method: Patients were identified from an institutional parotid tumor database. Patient history, demographics, pathologic diagnosis, treatment, and follow up were documented. Results: Eight patients were identified, 3 were males. The average age was 61 years old, and the most common tumors identified were pleomorphic sarcomas (3 patients). Presenting symptoms included: preauricular/cheek mass in 7 patients, facial pain (4), otalgia (4), aural fullness (3), and numbness (1). All patients received a parotidectomy, and 4 patients received adjuvant therapy of either radiation or chemoradiation. Post-operatively, there were 3 cases of distant recurrence, 2 cases of regional recurrence, and 1 case of local recurrence. There were 2 reports of death. Conclusion: Malignant mesenchymal tumors of the parotid are rare, represent varied histologies. Due to their aggressive nature, surgical resection with radiation and close follow-up may be an appropriate treatment regimen in controlling the disease.
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Metopimazine Mesylate (NG101) in Participants With Gastroparesis
Loesch, Jack , Hamza, Eyad , Pasricha, Pankaj J. , Nee, Judy , Cline, Michael, MacDougall, James A., Simons, Madison , Brown, J. Trig, Garg, Samita , Hoscheit, Matthew, Gabbard, Scott , Colle, Cyril De, Brown, John T , De Colle, Cyril , Lembo, Anthony , MacDougall, James, Lembo, Anthony

Mayo Clinic

American Journal of Gastroenterology | May 14, 2025 | Volume: 121 | Issue: 2 | Pages: 534-544

10.14309/ajg.0000000000003534 | PMID 40367443 Get It

INTRODUCTION: There is an urgent need for effective and safe treatment of gastroparesis. Metopimazine, a selective, peripherally restricted dopamine D 2 receptor antagonist, is used in France for the symptomatic treatment of nausea and vomiting and chemotherapy-induced nausea and vomiting. The aim of this study is to assess the safety and efficacy of oral NG101, the mesylate salt of metopimazine, for the treatment of gastroparesis. METHODS: We conducted a 12-week phase 2 multicenter trial with NG101 5, 10, and 20 mg 4 times a day versus placebo. The primary end point was the change in mean nausea severity from the Diabetic and Idiopathic Gastroparesis Symptoms Daily Diary (DIGS-DD) during weeks 7–12 of the Treatment Period from baseline. The DIGS-DD measured nausea, abdominal pain, early satiety, postprandial fullness, and vomiting at their worst in the past 24 hours using a 0-10 point numeric rating scale. Patient Global Impression of Change questionnaires, including nausea, were assessed weekly using a 7-point balanced ordinal score. RESULTS: Of 161 randomized participants (45.3% diabetic and 54.7% idiopathic), mean DIGS-DD nausea severity scores decreased from baseline during weeks 7–12 in all treatment groups, but these improvements were not statistically significant compared with placebo. However, there were statistically significant improvements in nausea Patient Global Impression of Change during weeks 1–12 for all treatment groups compared with placebo. Trends in safety and efficacy favored patients with idiopathic gastroparesis compared with those with diabetic gastroparesis. DISCUSSION: While NG101 did not meet statistical significance in its primary end point for reducing nausea severity, it demonstrated a favorable safety profile and significant improvement in some secondary end points. Further study is needed to determine whether NG101 is an effective treatment for patients with idiopathic gastroparesis.
In Young Patients Undergoing Total Hip Arthroplasty, Is There a Correlation Between Activity Level and Wear of Highly Cross-Linked Polyethylene?
Perez, Sergio F. Guarin , Restrepo, Diego J. , Lee, Sheng‐Hsun , Stuart, Michael , Trousdale, Robert T. , Berry, Daniel J. , Sierra, Rafael J. , Guarin Perez, Sergio F , Stuart, Michael B , Restrepo, Diego J. , Sierra, Rafael J , Berry, Daniel J

Mayo Clinic

JBJS Open Access | May 14, 2025 | Volume: 10 | Issue: 2 | Pages: No page available

10.2106/jbjs.oa.24.00242 | PMID 40371259 Get It

Background: Total hip arthroplasty (THA) effectively restores mobility, reduces pain, and enhances the quality of life of patients of all ages. Despite its benefits, concerns regarding the long-term effects of high-impact activities and sports on implant longevity require further study. This study investigated the effect of activity level on long-term radiographic wear of highly cross-linked polyethylene (HXLPE) in young patients undergoing THA. Methods: Between 1999 and 2008, 785 patients (909 hips) aged ≤50 underwent primary THA using first-generation HXLPE liners from 4 different vendors with either metal or ceramic heads. Functional activity and participation questionnaires, including the Hip Injury and Osteoarthritis Outcome Score (HOOS Jr), University of California Los Angeles (UCLA) activity scale, and High-Activity Arthroplasty Score (HAAS), were surveyed in 2018 to 2019. The response rate was 44%. Radiographic linear wear rates were measured using the ROMAN software in patients who had completed questionnaires and had radiographs taken at least 10 years apart, leaving a final cohort of 249 patients (284 hips). Multivariate analyses were performed to determine the relationship between HXLPE wear rates and activity scores. Results: At the time of the survey, approximately 10% of the patients performed high-impact activities not-recommended by consensus guidelines. The HXLPE linear wear rate was 0.036 mm/year (SD: 0.026). Patients with higher activity levels, as measured on the continuous UCLA/HAAS activity scale, did not exhibit increased wear (β = -0.0009; p = 0.31). Stair climbing was correlated with increased wear rates (β = 0.0066; p = 0.004), whereas walking (β = 0.0005; p = 0.66) and running (β = 0.0017; p = 0.30) were not significantly correlated. Patients performing nonrecommended activities did not show increased wear rates compared with those performing recommended activities (β = 0.0063; p = 0.19). Conclusions: Linear wear rates of first-generation HXLPE were not related to functional activity or participation in high-impact activities. Future research should include longitudinal assessments of activity levels and data on other potential complications related to high-impact sports to provide robust evidence regarding recommended activity level postoperatively. Level of Evidence: Level III , Retrospective Comparative Study. See Instructions for Authors for a complete description of levels of evidence.
From Data to Decisions: AI in Varicose Veins—Predicting, Diagnosing, and Guiding Effective Management
Pugalenthi, Lakshmi Sree , Garapati, Chris Alex Wesley, Maddukuri, Srivarshini , Kanwal, Fnu, Kumar, J. P. Senthil, Asadimanesh, Naghmeh, Dadwal, Surbhi, Ahluwalia, Vibhor, Senapati, Sidhartha Gautam , Arunachalam, Shivaram P. , Arunachalam, S P , Kumar, Jaspreet, Dadwal, Surbhi

Mayo Clinic

Journal of Vascular Diseases | May 14, 2025 | Volume: 4 | Issue: 2 | Pages: 19

10.3390/jvd4020019 Get It

Background: Varicose veins (VVs) of the lower limbs, characterized by palpable, dilated, and tortuous veins, affect 2–73% of the global population. Artificial intelligence (AI) offers significant potential to enhance healthcare efficiency and decision-making, particularly in managing VVs through improved risk factor identification, diagnosis, and treatment planning. Objective: This abstract explores the role of AI in VV management, focusing on its applications in risk detection, image analysis, treatment planning, and surgical interventions, while addressing challenges to its widespread adoption. Methods: AI leverages advanced techniques such as computer vision and deep learning to analyze patient data, including medical history, symptoms, physical examinations, and imaging (e.g., ultrasounds, venography). It identifies patterns in large datasets to support personalized treatment plans, early risk detection, and disease severity assessment. Results: AI demonstrates promise in automating VV detection and classification, assessing disease severity, and aiding treatment planning. It enhances surgical interventions through preoperative planning, intraoperative navigation, and recurrence risk prediction. However, its adoption is limited by a lack of large-scale studies, concerns over accuracy, and the need for regulatory and ethical oversight. Conclusion: AI has the potential to revolutionize VV management by improving diagnosis, treatment precision, and patient outcomes. Further research, validation, and integration are critical to overcoming current limitations and fully realizing AI’s capabilities in clinical practice.
Dynamic few-shot prompting for clinical note section classification using lightweight, open-source large language models
Miller, Kurt, Lu, Qiuhao , Hersh, William , Roberts, Kirk , Liu, Hongfang , Hersh, William , Liu, Hongfang , Miller, Kurt, Bedrick, Steven , Wen, Andrew , Roberts, Kirk E

Mayo Clinic

Journal of the American Medical Informatics Association | May 14, 2025 | Volume: 32 | Issue: 7 | Pages: 1164-1173

10.1093/jamia/ocaf084 | PMID 40460022 Get It

Abstract Objective Unlocking clinical information embedded in clinical notes has been hindered to a significant degree by domain-specific and context-sensitive language. Identification of note sections and structural document elements has been shown to improve information extraction and dependent downstream clinical natural language processing (NLP) tasks and applications. This study investigates the viability of a dynamic example selection prompting method to section classification using lightweight, open-source large language models (LLMs) as a practical solution for real-world healthcare clinical NLP systems. Materials and Methods We develop a dynamic few-shot prompting approach to classifying sections where section samples are first embedded using a transformer-based model and deposited in a vector store. During inference, the embedded samples with the most similar contextual embeddings to a given input section text are retrieved from the vector store and inserted into the LLM prompt. We evaluate this technique on two datasets comprising two section schemas, including varying levels of context. We compare the performance to baseline zero-shot and randomly selected few-shot scenarios. Results The dynamic few-shot prompting experiments yielded the highest F1 scores in each of the classification tasks and datasets for all seven of the LLMs included in the evaluation, averaging a macro F1 increase of 39.3% and 21.1% in our primary section classification task over the zero-shot and static few-shot baselines, respectively. Discussion and Conclusion Our results showcase substantial performance improvements imparted by dynamically selecting examples for few-shot LLM prompting, and further improvement by including section context, demonstrating compelling potential for clinical applications.
Development of a Patient Education Pathway for a Psychiatric Nurse Consult Service
Kuntz, Madeline, Linden, Tracy, Kinstler, Daniel Paul, Forsyth, Diane McNally, Forsyth, Diane, Linden, Tracy

Mayo Clinic

Journal of Psychosocial Nursing and Mental Health Services | May 13, 2025 | Volume: 63 | Issue: 11 | Pages: 15-21

10.3928/02793695-20250505-01 | PMID 40359447 Get It

Purpose: The current quality improvement project aimed to improve functionality within a psychiatric consult liaison nurse (PCLN) service through implementation of an educational pathway. Method: Pre- and postintervention qualitative interviews were conducted with eight PCLNs, and themes were generated via content analysis. Quantitative surveys were also conducted, and data were analyzed using means and standard deviations. Paired t tests were used to test for significance. Results: Qualitative results identified five themes: Flexibility vs. Uncertainty , Ambiguity vs. Direction , Structured vs. Unstructured Education , Efficiency/Time Management , and Communication . Quantitative surveys indicated the intervention improved the consistency of the psychoeducation provided ( p = 0.03) and enhanced the structure of the PCLN role ( p = 0.04). The intervention did not significantly improve communication between PCLNs and medical–surgical nurses. Conclusion: Qualitative findings showed that the educational pathway improved efficiency, time management, and communication, and quantitative findings showed it can help with consistency and structure to the role. Implementing an educational pathway for PCLNs is feasible and effective for health care systems.
Global Sociodemographic Disparities in Ischemic Heart Disease Mortality According to Sex, 1980 to 2021
Sayed, Ahmed , Michos, Erin D. , Návar, Ann Marie , Virani, Salim S. , Brewer, LaPrincess C. , Manson, JoAnn E. , Manson, JoAnn E , Brewer, LaPrincess C , Michos, Erin D , Navar, Ann Marie

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | May 13, 2025 | Volume: 18 | Issue: 7 | Pages: No page available

10.1161/circoutcomes.124.011648 | PMID 40358980 Get It

BACKGROUND: Mortality due to ischemic heart disease (IHD) has declined in countries with high socioeconomic development. Whether these declines extend to other settings, and whether socioeconomic development influences IHD mortality among men and women differently, is unknown. METHODS: We obtained annual data on sex-specific IHD mortality rates for countries/territories in the GBD study (Global Burden of Disease) from 1980 to 2021. The sociodemographic index (SI), a measure of socioeconomic development, was retrieved for each country/territory. Age-adjusted IHD mortality rates were modeled as a smooth function of sex, year, and SI. RESULTS: From 1980 to 2021, IHD mortality rates did not decrease in low SI settings for men or women. In contrast, mortality rates relative to 1980 declined by >25% in average SI settings (age-adjusted mortality per 100 000, 153–107 for women and 218–161 for men) and >50% in high SI settings (age-adjusted mortality per 100 000, 162–69 for women and 258–114 for men). Comparing the 20th versus 80th percentile of SI in 2021 (corresponding to lower versus higher socioeconomic development), mortality rates were 81% higher for men and 111% higher for women living in socioeconomically deprived settings ( P for difference by sex: 0.01), although absolute differences were larger in men. The association of low SI with higher IHD mortality was especially pronounced for mortality attributable to environmental/occupational risk factors (eg, particulate matter air pollution, lead exposure, and extremes of temperature), with mortality rates being 174% higher among women and 199% higher among men. CONCLUSIONS: Across the past 4 decades, low socioeconomic development was associated with no improvement in IHD mortality rates for men or women, in contrast to the large reductions observed in settings with high socioeconomic development. In contemporary settings, socioeconomic deprivation is associated with larger relative excess mortality in women and larger absolute excess mortality in men.
Core GRADE 4: rating certainty of evidence—risk of bias, publication bias, and reasons for rating up certainty
Guyatt, Gordon , Eachempati, Prashanti, Hultcrantz, Monica , Chu, Derek K. , Flórez, Iván D. , Agoritsas, Thomas , Yao, Liang , Vandvik, Per Olav , Brignardello‐Petersen, Romina , Guyatt, Gordon , Chu, Derek K , Wang, Ying , Eachempati, Prashanti , Iorio, Alfonso , Murad, M. Hassan , Hemkens, Lars G. , Montori, Víctor M.

Mayo Clinic

BMJ | May 13, 2025 | Volume: 389 | Issue: No issue available | Pages: e083864

10.1136/bmj-2024-083864 | PMID 40360206 Get It

Prevalence, Diagnosis, and Treatment of Cardiac Tumors: A Narrative Review
Rahouma, Mohamed , Mohsen, Hosny , Morsi, Mahmoud , Khairallah, Sherif , Azab, Lilian, Abdelhemid, Maya, Ahmed, Magdy M. El‐Sayed , El-Sayed Ahmed, Magdy M , Kumar, Akshay , Rahouma, Mohammed

Mayo Clinic

Journal of Clinical Medicine | May 13, 2025 | Volume: 14 | Issue: 10 | Pages: 3392

10.3390/jcm14103392 | PMID 40429390 Get It

Cardiac tumors, though rare, present significant diagnostic and therapeutic challenges due to their heterogeneous nature and anatomical complexity. This narrative review synthesizes current evidence on prevalence, diagnostic modalities, and management strategies for primary and metastatic cardiac tumors. Echocardiography, cardiac MRI, and CT remain cornerstone imaging tools for differentiating tumors from non-neoplastic masses, while advances in PET/CT and tissue characterization techniques refine staging and treatment planning. Surgical resection with clear margins (R0) is critical for resectable tumors, particularly benign myxomas, though malignant tumors like sarcomas require multimodal approaches combining surgery, radiotherapy, and systemic therapies. Emerging strategies such as heart autotransplantation and staged resections offer promise for complex cases, while oligometastatic disease management highlights the role of stereotactic radiotherapy and immunotherapy. Key challenges include standardizing resection margins, optimizing neoadjuvant therapies, and addressing high recurrence rates in malignancies. Future directions emphasize integrating AI-driven imaging analysis, molecular biomarkers, and genomic profiling to personalize therapies, alongside global registries to enhance data on rare tumors. Equitable access to advanced diagnostics and multidisciplinary collaboration are essential to improve outcomes. This review underscores the need for standardized guidelines, technological innovation, and patient-centered research to address gaps in cardiac oncology.